Tiflamizole is a fluorinated diarylamidazole derivative patented by du Pont de Nemours, E. I., and Co. as an anti-inflammatory agent. Tiflamizole acts as a non-steroidal anti-inflammatory drug, that exerts potent inhibition of prostaglandin synthesis and exhibits anti-inflammatory, antipyretic, and analgesic activity in animal studies. Preliminary studies in animals and man have shown that Tiflamizole is rapidly absorbed from the gastrointestinal tract, is highly protein-bound, and is slowly excreted. Toxicity studies in animals focused on the gastrointestinal tract. Short-term toxicity studies in rats indicated that the margin of safety of Tiflamizole is greater than that for piroxicam, ibuprofen, or sulindac.